Treatment News : Zoledronate Effectively Treats HIV-Related Bone Mineral Loss

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » December 2008

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


December 5, 2008

Zoledronate Effectively Treats HIV-Related Bone Mineral Loss

A one-time dose of zoledronate (Reclast) increased bone health for up to one year in HIV-positive patients with bone mineral deficiency, according to a study published in the January 2 issue of AIDS.

Bone mineral loss—known as osteopenia when it is mild to moderate and osteoporosis when it is more severe—is a disorder that most commonly strikes women after they’ve gone through menopause, people with thyroid problems and people who’ve taken corticosteroids for many years. There have been increasing reports in recent years, however, of younger HIV-positive women and men with bone mineral loss. Unfortunately, few studies have looked at osteopenia and osteoporosis treatments in people living with HIV.

To explore the potential of zoledronate, which has been approved as a once yearly injection for women with osteopenia and osteoporosis, Jeannie Huang, MD, MPH, from the University of California in San Diego, and her colleagues first screened 143 HIV-positive patients from their clinic. Thirty patients met the study qualification of having significantly reduced bone density at either the lower spine or hip and were randomized to receive either a 5 milligram injection of zoledronate or a placebo. The average age of the participants was 48, and 27 were men.

Twelve months after the one-time injection, Dr. Huang’s team found that bone density increased significantly in both the lower spine and hip in people who received zoledronate. Bone density increased only slightly at the lower spine and actually decreased in the hip in people who received the placebo. All the participants had increased their calcium intake during the study period, but to an equal degree, and this did not affect the study’s outcome.

One patient on zoledronate did experience uveitis—an inflammation of the eye—a known side effect of the drug. Otherwise the drug was generally well tolerated. The authors acknowledge that the long-term safety of zoledronate, given over several years, will need to be studied, but they conclude that it is a good treatment candidate for people with HIV and osteopenia or osteoporosis.

Search: zoledronate, Reclast, bone mineral, bone density, menopause, thyroid, corticosteroid

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.